HOW TO INCLUDE ECONOMICS IN COCHRANE REVIEW PROTOCOLS



Part One: Background, objectives, outcome measures and types of studies

COI statement

I have no actual or potential conflict of interest in relation to this presentation

Campbell & Cochrane Economics Methods Group http://methods.cochrane.org/economics/

Learning objectives

- Incorporate economic perspectives into 'Background'
- Formulate an 'Objective' for a critical review of health economic studies
- Identify measures of resource use, costs and cost-effectiveness to be included in 'Types of outcome measures'
- Identify types of health economic studies to be included in 'Types of studies'

Preliminary points

- Advisory support from a health economist useful
 - Check with CRG health economist advisor?
 - Contact Economics Methods Group janice.legge@newcastle.ac.uk
- Focus on how to prepare <u>protocol</u> for a critical review of health economics studies



<u>Home</u> > <u>Part 3: Special topics</u> > 15 Incorporating economics evidence

Chapter 15: Incorporating economics evidence

Authors: Ian Shemilt, Miranda Mugford, Sarah Byford, Michael Drummond, Eric Eisenstein, Martin Knapp, Jacqueline Mallender, David McDaid, Luke Vale and Damian Walker on behalf of the Campbell and Cochrane Economics Methods Group.

Key points

- Economics is the study of the optimal allocation of limited resources for the production of benefit to society and is therefore relevant to any healthcare decision.
- · Optimal decisions also require best evidence of effectiveness.
- This chapter describes methods for incorporating economics perspectives and evidence into Cochrane reviews, with a focus on critical review of health economics studies.
- Incorporating economics perspectives and evidence into Cochrane reviews can enhance their usefulness and applicability for healthcare decision-making and new economic analyses.
- 15.1 The role and relevance of economics evidence in Cochrane reviews
- 15.2 Planning the economics component of a Cochrane review
- 15.3 Locating studies
- 15.4 Selecting studies and collecting data
- 15.5 Addressing risk of bias
- 15.6 Analysing and presenting results
- 15.7 Addressing reporting biases
- 15.8 Interpreting results

Box15.8.a: Highlighting a need for further economics studies in

15.9 Conclusions

>

Additional material

Search

Part 2: General methods for Cochrane reviews

7 Selecting studies and collecting data 8 Assessing risk of bias in included studies

≥ 10 Addressing reporting biases

13 Including non-randomized studies

15 Incorporating economics evidence

> 15.5 Addressing risk of bias

> 15.3 Locating studies

? 15.8 Interpreting results

15.9 Conclusions
 15.10 Chapter information

? 15.11 References

22 Overviews of reviews

16 Special topics in statistics 17 Patient-reported outcomes

19 Prospective meta-analysis

18 Reviews of individual patient data

20 Qualitative research and Cochrane reviews

21 Reviews in public health and health promotion

5 Defining the review question and developing crit

9 Analysing data and undertaking meta-analyses

11 Presenting results and 'Summary of findings' ta

15.1 The role and relevance of economics evice

15.2 Planning the economics component of a

Pox15.8.a: Highlighting a need for further ecor

Box15.10.a: The Campbell and Cochrane Econ-

> 15.4 Selecting studies and collecting data

15.6 Analysing and presenting results
15.7 Addressing reporting biases

12 Interpreting results and drawing conclusions

Contents

Handbook information

Part 3: Special topics


> 14 Adverse effects

Rart 1: Cochrane reviews

6 Searching for studies

? Front page





Background: Describe economic burden of condition


Faecal incontinence...can be a debilitating problem with medical, social and economic implications... In the United States more than \$400 million is spent each year on a range of both urinary and faecal incontinence products... During 1991 the direct costs of pads, appliances and other prescription items throughout hospitals and long term care settings in the UK for incontinence in general was estimated at £68 million... With the rise in numbers of elderly people in the world, this condition will be an increasing challenge to both healthcare services and home carers.

Background: Describe potential impacts of intervention(s) on resource use (costs)

- 'Resource inputs' ('input costs')
 - e.g. staff time and skills, equipment, devices, drugs, hospital care, patient out-of-pocket expenses...
- `Resource consequences' ('downstream costs')
 - e.g. health care and other resources used to manage sequelae and complications of treatment, time off work...

Background: Highlight issue of costeffectiveness

It is important to consider whether use of Bone Morphogenetic Protein is worthwhile...given the incremental costs (resource use) and benefits (effects) which may be associated with the intervention.



Objectives: Clinical effects

To assess the [clinical] effectiveness of Bone Morphogenetic Protein for fracture healing in skeletally mature adults, compared to current standard treatments

Objectives: Economics

To critically appraise and summarise current evidence on the [resource use/ costs/ and cost-effectiveness] associated with [intervention or comparison] for [health problem] for/in [types of people, disease or problem and setting if specified]


Objectives: Economics

To critically appraise and summarise current evidence on the (incremental) resource use, costs and costeffectiveness of Bone Morphogenetic Protein for fracture healing in skeletally mature adults, compared to current standard treatments


Objectives: Economics


To critically appraise and summarise current evidence on the (incremental) resource use, costs and costeffectiveness of Bone Morphogenetic Protein for fracture healing in skeletally mature adults, compared to current standard treatments

Use of 'Clinical event pathway descriptions'



Use of 'Clinical event pathway descriptions'





- Resource use
- Costs
- Cost-effectiveness

- Magnitude
- Time horizon
- Analytic perspective

Magnitude and analytic perspective

Bone Morphogenetic Protein for fracture healing

- Costs of acute treatment and care
- Costs of revisional procedures
- Costs of secondary interventions
- Cost of antibiotics
- Cost of outpatient visits
- Cost of travel to outpatient visits
- Cost of physiotherapy
- Cost of child care
- Lost wages
- Lost productivity (work output)
- Wages paid to temporary staff to cover absence

Resource use

- Specific items of resource use
 - Length of hospital stay (days)
 - Duration of operation (minutes)
 - Outpatient visits (number)
 - Pharmaceuticals (treatment duration and dosage)
 - Time to return to work (days)

- Resource use
 - Exceptions
 - Other direct resource use associated with complications of treatment


Costs

- Specific cost items?
 - Cost of hospital stay
 - Cost of operation
 - Cost of outpatient visits
- Specific cost categories
 - Direct medical costs
 - Non-medical costs

Costs

- Level
 - Cost of 'X' per patient (specific cost items)
 - Average (mean) cost of 'X' per patient
 - Total direct medical costs per patient
 - Average (mean) total direct medical costs per patient
 - Total non-medical costs per patient
 - Average (mean) total non-medical costs per patient

- Cost-effectiveness
 - Incremental cost-effectiveness ratios (ICERs)
 - Incremental cost per quality-adjusted life year (QALY)
 - Incremental cost per disability-adjusted life year (DALY)
 - Incremental cost-benefit ratios
 - Net benefits



Types of studies: Economic evaluation studies

Are both costs (inputs) and consequences (outputs) of the alternatives examined?

		No		Yes
		Examines only consequences	Examines only costs	
	No	1A Partial evaluation 1B		2 Partial evaluation
١		Outcome description	Cost description	Cost-outcome description
		3A Partial evaluation 3B		4 Full economic evaluation
	Yes	Efficacy or effectiveness evaluation	Cost analysis	Cost-effectiveness analysis (CEA) Cost-utility analysis (CUA) Cost-benefit analysis (CBA)

Is there comparison of two or more alternatives?

Bone Morphogenetic Protein (Example)

Objectives

To critically appraise and summarise current evidence on the (incremental) resource use, costs and costeffectiveness of Bone Morphogenetic Protein for fracture healing in skeletally mature adults, compared to current standard treatments

Types of intervention

BMP versus surgery alone

BMP versus surgery with or without bone graft

BMP and bone substitutes versus surgery and bone substitutes

Types of studies: Economic evaluation studies

Are both costs (inputs) and consequences (outputs) of the alternatives examined?

		No		Yes
		Examines only consequences	Examines only costs	
	No	1A Partial evaluation 1B		2 Partial evaluation
١		Outcome description	Cost description	Cost-outcome description
		3A Partial evaluation 3B		4 Full economic evaluation
	Yes	Efficacy or effectiveness evaluation	Cost analysis	Cost-effectiveness analysis (CEA) Cost-utility analysis (CUA) Cost-benefit analysis (CBA)

Is there comparison of two or more alternatives?

Types of studies: Full economic evaluation studies

- Cost-effectiveness analysis: cost per unit of effect (ICER)
- Cost utility analysis: cost per QALY/ cost per DALY (ICER)
- Cost-benefit analysis: cost-benefit ratio/ net benefit

Types of studies: health economics studies

Comparative health economics studies

Resource utilisation studies

'Comparative' resource utilisation studies (e.g. resource use measured within an RCT)

Partial economic evaluations Cost analyses

Full economic evaluations

Cost-effectiveness analyses Cost-utility analyses Cost-benefit analyses

Types of studies: health economics studies

Types of studies

Randomised controlled trials. Full economic evaluations (cost-effectiveness analyses, cost-utility analyses and cost-benefit analyses), cost analyses and comparative resource utilisation studies.

Types of studies: the issue of scope

- Full economic evaluations, cost analyses and comparative resource utilisation studies can all be conducted alongside an RCT
- Full economic evaluations can also be conducted as 'model-based economic evaluations'
- Cost analyses and comparative resource utilisation studies can also be conducted as 'stand-alone' studies

Types of studies: the issue of scope

Option 1

Include only 'empirical' health economics studies conducted alongside single, primary studies of effects which meet eligibility criteria for the review of intervention effects

Types of studies: health economics studies

Types of studies (Option 1)

Randomised controlled trials. Full economic evaluations (cost-effectiveness analyses, cost-utility analyses and cost-benefit analyses), cost analyses and comparative resource utilisation studies conducted alongside a randomised controlled trial.

Types of studies: the issue of scope

Option 2

Include 'empirical' health economics studies conducted alongside single, primary studies of effects which meet eligibility criteria for the review of intervention effects

AND

Health economics studies utilising effects data sourced from one or more single, primary studies meeting eligibility criteria for the review of intervention effects

Types of studies: health economics studies

Types of studies (Option 2)

Randomised controlled trials. Full economic evaluations (cost-effectiveness analyses, cost-utility analyses and cost-benefit analyses) conducted alongside a randomised controlled trial or those utilising effects data generated using either a meta-analysis of randomised controlled trials or a single randomised controlled trial. Cost analyses and comparative resource utilisation studies conducted alongside a randomised controlled trial.

Types of studies: the issue of scope

Option 3

Include all health economics studies meeting eligibility criteria, populations and comparisons, whether or not conducted alongside or utilising effects data sourced from studies which meet eligibility criteria for the review of intervention effects

Types of studies: health economics studies

Types of studies (Option 3)

Randomised controlled trials. Full economic evaluations (cost-effectiveness analyses, cost-utility analyses and cost-benefit analyses), cost analyses and comparative resource utilisation studies – any study design.



Trusted evidence. Informed decisions. Better health. Cochrane Methods | Cochrane Library | Cochrane.org | Admin

Welcome

About us

Resources

nt Publications

Contact us

Methods Groups




The Campbell & Cochrane Economics Methods Group (CCEMG) is an international network of individuals with an interest and expertise in approaches to evidence synthesis that combine economics and systematic review methods. CCEMG strives to promote the inclusion of economic perspectives and evidence in systematic reviews of health care, social welfare, education and criminal justice interventions.

This is achieved through our development and provision of methods guidance, training, peer review and advisory support for economics components of reviews. CCEMG is a Methods Groups of Cochrane and a subgroup of The Campbell Collaboration Methods Coordinating Group.



http://methods.cochrane.org/economics/



Edited by
Ian Shemilt
Miranda Mugford
Luke Vale
Kevin Marsh
Cam Donaldson



HOW TO INCLUDE ECONOMICS IN COCHRANE REVIEW PROTOCOLS



Part One: Background, objectives, outcome measures and types of studies

Campbell & Cochrane Economics Methods Group http://methods.cochrane.org/economics/